stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) EBITDA
RadNet, Inc.'s EBITDA for fiscal 2025 was $279.3M, down 11.5% from $315.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $307.7M. Over the past ten years it has ranged from $105.1M (fiscal 2015) to $315.5M (fiscal 2024); the current reading is higher than 82% of that period. RadNet, Inc. ranks 17th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $279.3M | (11.47%) |
| FY2024 | $315.5M | 7.02% |
| FY2023 | $294.8M | 24.12% |
| FY2022 | $237.5M | (8.72%) |
| FY2021 | $260.2M | 31.23% |
| FY2020 | $198.3M | (10.50%) |
| FY2019 | $221.5M | 105.71% |
| FY2018 | $107.7M | (10.51%) |
| FY2017 | $120.3M | 9.26% |
| FY2016 | $110.1M | 4.79% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $102.1M | 167.76% |
| Mar 2026 | $38.1M | (54.98%) |
| Dec 2025 | $84.7M | 2.35% |
| Sep 2025 | $82.8M | (1.72%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ICLR ICON PLC compare | $1.1B |
| QGEN QIAGEN N.V. compare | $651.0M |
| SHC Sotera Health Company compare | $537.0M |
| RDNT RadNet, Inc. | $307.7M |
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| GRAL GRAIL, Inc. compare | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement